Does RASBURICASE Cause Product use in unapproved indication? 76 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 76 reports of Product use in unapproved indication have been filed in association with RASBURICASE (Elitek). This represents 8.6% of all adverse event reports for RASBURICASE.
76
Reports of Product use in unapproved indication with RASBURICASE
8.6%
of all RASBURICASE reports
10
Deaths
65
Hospitalizations
How Dangerous Is Product use in unapproved indication From RASBURICASE?
Of the 76 reports, 10 (13.2%) resulted in death, 65 (85.5%) required hospitalization, and 5 (6.6%) were considered life-threatening.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RASBURICASE. However, 76 reports have been filed with the FAERS database.
What Other Side Effects Does RASBURICASE Cause?
Tumour lysis syndrome (116)
Methaemoglobinaemia (92)
Off label use (90)
Bacterial infection (75)
Fungal infection (73)
Cellulitis (72)
Clostridium difficile colitis (72)
Lymphoid tissue hypoplasia (72)
Lymphopenia (72)
Drug ineffective (71)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which RASBURICASE Alternatives Have Lower Product use in unapproved indication Risk?
RASBURICASE vs RAVULIZUMAB
RASBURICASE vs RAVULIZUMAB-CWVZ
RASBURICASE vs REBAMIPIDE
RASBURICASE vs REBETOL
RASBURICASE vs REBIF